Collaboration Between Protalix Biotherapeutics and Secarna Pharmaceuticals for Rare Disease Innovations Protalix BioTherapeutics and Secarna Pharmaceuticals have teamed up to develop antisense oligonucleotide therapies targeting rare renal diseases, merging expertise to fill significant medical needs.

Collaboration Between Protalix Biotherapeutics and Secarna Pharmaceuticals for Rare Disease Innovations #United_States #Protalix #Secarna #OligoCreator #Carrying_out_clinical_stages_in_various_locations

Protalix BioTherapeutics Reports Third Quarter 2025 Performance and Future Plans Protalix BioTherapeutics announces its Q3 2025 performance, highlighting revenue growth and future clinical trials for innovative treatments in biotechnology.

Protalix BioTherapeutics Reports Third Quarter 2025 Performance and Future Plans #Israel #Elfabrio #Carmiel #PRX-115 #Protalix

Protalix BioTherapeutics to Showcase Innovations at Global Investment Conference Protalix BioTherapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, showcasing its innovative breakthroughs in biopharmaceuticals.

Protalix BioTherapeutics to Showcase Innovations at Global Investment Conference #USA #New_York_City #biopharmaceuticals #Protalix #H.C._Wainwright

Protalix BioTherapeutics Announces Significant Growth in Q2 2025 Financial Results Protalix BioTherapeutics reports substantial revenue growth for Q2 2025, driven by increased sales of Elfabrio. The company highlights expansion plans and leadership changes.

Protalix BioTherapeutics Announces Significant Growth in Q2 2025 Financial Results #Israel #Elfabrio #Carmiel #PRX-115 #Protalix

Protalix BioTherapeutics Welcomes Gilad Mamlok as New CFO Amid Strategic Growth Plans Protalix BioTherapeutics has appointed Gilad Mamlok as its new CFO, effective August 24, 2025. With over 30 years of experience, he aims to enhance the company's growth strategy.

Protalix BioTherapeutics Welcomes Gilad Mamlok as New CFO Amid Strategic Growth Plans #Israel #CFO #Carmiel #Protalix #Gilad_Mamlok

Protalix BioTherapeutics to Showcase Innovations at iAccess Alpha Conference 2025 Protalix BioTherapeutics will present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025, focusing on innovative biopharmaceutical solutions and investment opportunities.

Protalix BioTherapeutics to Showcase Innovations at iAccess Alpha Conference 2025 #Israel #Carmiel #Protalix #iAccess_Alpha #Conference_2025